We prioritize environmental sustainability within and beyond AbbVie and engage our workforce to steward sustainability. Globally we’ve expanded our use of electric and hybrid vehicles in our fleet and invested in electric vehicle charging stations at our facilities. We’ve reduced our natural gas and electricity by discontinuing a legacy product’s production in our North Chicago facility. In our Liege Belgium site, we’ve installed a photovoltaic solar system that can provide up to one third of the site’s annual electricity needs, reducing greenhouse gas emissions by approximately 120 metric tonsAt the heart of AbbVie lies a single guiding belief: That our commitment to science is a commitment to better our society. As members of the wide-reaching scientific community, we cannot separate our work from the world .We take pride in our groundbreaking drug discovery and development. But it is our ability to deliver that sets us apart and allows us to uniquely address the needs of our patients and the needs of our times. In this pursuit, progress is our policy. We are committed to collaboration – with our communities, our patients and customers, our employees, policymakers, and the public. We are dedicated to diversity. We nurture the careers of diverse talent, support diverse communities, and facilitate global scientific partnership.At AbbVie, we pride ourselves in our long tradition of strong financial controls and corporate governance. AbbVie’s Board of Directors plays a vital role in providing strategic direction and overseeing management performance on behalf of stakeholders. Ten of the eleven members on the board are independent directors. The chairs and members of the board’s Audit Committee, Compensation Committee, Public Policy and Sustainability Committee, and Nominations and Governance Committee are independent directors.AbbVie has historically reported substantial revenues and maintained a strong level of profitability. The company’s portfolio of pharmaceutical products, including blockbuster drugs, contributes significantly to its revenue streams. The company operates in a range of therapeutic areas, which helps mitigate risks associated with overreliance on a single drug or therapeutic category. AbbVie’s ability to develop and bring new drugs to market is crucial for long-term financial sustainability. The success of drugs in the company’s pipeline can impact future revenue growth. Like other pharmaceutical companies, AbbVie invests heavily in research and development to innovate and discover new treatments. The success of R&D efforts can influence the company’s future growth.The AbbVie Dividend Reinvestment Plan offers registered stockholders an opportunity to purchase additional shares, commission-free, through automatic dividend reinvestment and/ or optional cash investments. Interested persons may contact the transfer agent. This past year was a highly productive year and we executed well across our diverse portfolio to drive growth. Our full-year adjusted Earnings Per Share (EPS) of $13.77 reflects double-digit growth over the prior year, and our total net revenues of more than $58 billion reflect a 5.1% increase on an operational basis over 2021. These results were driven by the growth of our neuroscience portfolio and the outstanding performance of our immunology growth drivers, Skyrizi and Rinvoq which generated nearly $7.7 billion last year combined. We also continued our strong commitment to science and innovation investing $7.1 billion in adjusted R&D and today our pipeline includes more than 80 programs across all development stages, which further supports our long-term growth outlook.